Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Sparc

    Jump to

    • SPARC shares crash 19% after Psoriasis drug fails to deliver in trials

      SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company will halt further development and assess next steps

    • SPARC up 12% ahead of update on clinical programs, R&D pipeline this week

      SPARC has a market capitalisation close to Rs 7,600 crore and the shares are down by 23% so far this year. On charts, the share has given a strong breakout rising above the 10 and 20 EMA.

    • Sun Pharma Advanced slips 5% on halting Parkinson's drug trial

      The Sun Pharma Advanced Research Company stock has gained 40 percent this year against a 4 percent rise in the benchmark Nifty50

    • Sun Pharma inks licensing pact with SPARC to commercialise medication in US market

    • Trade Spotlight | What should you do with Shoppers Stop, Sharda Cropchem, SPARC, Hitachi Energy and Bajaj Auto?

    • SPARC inks licensing pact with Visiox Pharma for ophthalmic products

    • Dilip Shanghvi resigns as MD of SPARC: Here's what you need to know about him

    • Union Education Ministry releases Rs 80 crore to IIT Kharagpur for second phase of SPARC

    • 'Nifty to head towards 12,700 levels, but money will likely be made in mid & smallcaps'

    • Abraxis Bioscience LLC dismisses patent infringement complaint against SPARC

    • Market Headstart: Nifty50 seen opening higher; 3 stocks which could give 5-10% return

    • Market Headstart | Nifty likely to open flat; 3 stocks that could give 7-12% return

    • Podcast | Stock picks of the day: Nifty could remain in upward consolidation mode

    • SPARC, Schrödinger announce research collaboration for novel CNS therapeutics

    • SPARC jumps 8% on successful pivotal bioequivalence study for cancer drug

    • Market Now: Jewellery stocks shine - PC Jeweller, Titan up 3-4%; ICICI Bank top gainer

    • SPARC jumps 4% on topline results of PIF and low dose PK study for dry powder inhaler

    • Stocks in the news: Bajaj Auto, Laurus Labs, M&M, Bhushan Steel, SPARC, Deccan Cements

    • SPARC spikes 7% on USFDA's complete response letter for Xelpros

    • Sensex, Nifty continue to fall; Midcap breaks 200-DMA, SPARC up

    • Buy Tata Steel, sell Infosys: Mitesh Thacker

    • Cadila Healthcare may test Rs 393: Rajat Bose

    • Buy SPARC, says Mitesh Thacker

    • SPARC Q4 net loss widens to Rs. 9.6 crore

    • Hold SPARC, says Sharmila Joshi

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347